ATE554169T1 - Smad7-inhibitoren zur behandlung von krankheiten des zns - Google Patents
Smad7-inhibitoren zur behandlung von krankheiten des znsInfo
- Publication number
- ATE554169T1 ATE554169T1 AT02790321T AT02790321T ATE554169T1 AT E554169 T1 ATE554169 T1 AT E554169T1 AT 02790321 T AT02790321 T AT 02790321T AT 02790321 T AT02790321 T AT 02790321T AT E554169 T1 ATE554169 T1 AT E554169T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- cns diseases
- smad7 inhibitors
- diseases
- disease
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 101700026522 SMAD7 Proteins 0.000 title abstract 2
- 102000049873 Smad7 Human genes 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 208000015114 central nervous system disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01126140 | 2001-11-02 | ||
| PCT/EP2002/012221 WO2003037368A2 (en) | 2001-11-02 | 2002-10-31 | Smad7 inhibitors for the treatment of cns diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE554169T1 true ATE554169T1 (de) | 2012-05-15 |
Family
ID=8179155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02790321T ATE554169T1 (de) | 2001-11-02 | 2002-10-31 | Smad7-inhibitoren zur behandlung von krankheiten des zns |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7700572B2 (de) |
| EP (1) | EP1456380B1 (de) |
| AT (1) | ATE554169T1 (de) |
| AU (1) | AU2002363182A1 (de) |
| CY (1) | CY1112932T1 (de) |
| DK (1) | DK1456380T3 (de) |
| ES (1) | ES2388968T3 (de) |
| PT (1) | PT1456380E (de) |
| SI (1) | SI1456380T1 (de) |
| WO (1) | WO2003037368A2 (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2388968T3 (es) * | 2001-11-02 | 2012-10-22 | Giuliani International Limited | Inhibidores de Smad7 para el tratamiento de enfermedades del SNC |
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| SG10202103401QA (en) | 2008-03-17 | 2021-05-28 | Scripps Research Inst | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
| PT3121280T (pt) | 2008-11-13 | 2025-07-01 | Nogra Pharma Ltd | Composições antissentido e método de fabrico e utilização das mesmas |
| US9468649B2 (en) | 2008-12-05 | 2016-10-18 | The Regents Of The University Of California | Methods of treating epilepsy with transforming growth factor beta inhibitors |
| ES2938049T3 (es) | 2009-10-16 | 2023-04-04 | Scripps Research Inst | Inducción de células pluripotentes |
| AU2011235212B2 (en) | 2010-03-31 | 2014-07-31 | The Scripps Research Institute | Reprogramming cells |
| KR102703637B1 (ko) | 2010-12-22 | 2024-09-05 | 페이트 세러퓨틱스, 인코포레이티드 | 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼 |
| ES2392862B1 (es) * | 2011-06-02 | 2013-11-05 | Fundación Para La Investigación Biomédica Del Hospital Universitario Ramón Y Cajal | Tgf-beta y/o smad3 como marcadores de diagnóstico y/o pronóstico de alfa-sinucleinopatías |
| MX350087B (es) | 2011-09-15 | 2017-08-24 | Nogra Pharma Ltd | Metodos para vigilar la capacidad de respuesta a la terapia anti-smad7. |
| CN107252492A (zh) * | 2012-04-18 | 2017-10-17 | 诺格尔制药有限公司 | 治疗糖尿病和/或促进胰岛移植后存活的方法 |
| GB201300684D0 (en) | 2013-01-15 | 2013-02-27 | Apitope Int Nv | Peptide |
| US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| KR102340553B1 (ko) | 2014-03-04 | 2021-12-21 | 페이트 세러퓨틱스, 인코포레이티드 | 개선된 재프로그래밍 방법 및 세포 배양 플랫폼 |
| KR20170005058A (ko) | 2014-05-09 | 2017-01-11 | 노그라 파마 리미티드 | 염증성 장 질환을 치료하는 방법 |
| US10023879B2 (en) | 2014-06-04 | 2018-07-17 | Fate Therapeutics, Inc. | Minimal volume reprogramming of mononuclear cells |
| MA43331A (fr) | 2014-10-17 | 2017-08-23 | Nogra Pharma Ltd | Procédés et compositions pour le traitement d'un sujet au moyen d'un oligonucléotide antisens de smad7 |
| CN114058582A (zh) | 2015-01-26 | 2022-02-18 | 菲特治疗公司 | 用于诱导造血细胞分化的方法和组合物 |
| AU2016338680B2 (en) | 2015-10-16 | 2022-11-17 | Fate Therapeutics, Inc. | Platform for the induction and maintenance of ground state pluripotency |
| CN115927199A (zh) | 2015-11-04 | 2023-04-07 | 菲特治疗公司 | 用于诱导造血细胞分化的方法和组合物 |
| ES2953925T3 (es) | 2015-11-04 | 2023-11-17 | Fate Therapeutics Inc | Ingeniería genómica de células pluripotentes |
| US11162097B2 (en) | 2016-02-23 | 2021-11-02 | Nogra Pharma Limited | Methods of treating intestinal fibrosis using SMAD7 inhibition |
| WO2019051173A1 (en) * | 2017-09-08 | 2019-03-14 | Ionis Pharmaceuticals, Inc. | MODULATORS OF SMAD7 EXPRESSION |
| JP2023527525A (ja) * | 2020-05-22 | 2023-06-29 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | インターフェロン誘導オリゴヌクレオチド二重鎖および使用方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096722A (en) * | 1990-08-14 | 2000-08-01 | Isis Pharmaceuticals Inc. | Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases |
| WO1994002499A1 (en) * | 1992-07-27 | 1994-02-03 | Hybridon, Inc. | Oligonucleotide alkylphosphonothioates |
| US6884787B2 (en) * | 2001-07-14 | 2005-04-26 | Isis Pharmaceuticals, Inc. | Antisense modulation of transforming growth factor-beta 3 expression |
| EP0667148B1 (de) * | 1992-11-06 | 2002-07-03 | Hisamitsu Pharmaceutical Co., Inc. | Perorale pharmazeutische zubereitung mit freisetzung im unteren verfdauungstrakt |
| US20020177568A1 (en) * | 1992-12-07 | 2002-11-28 | Stinchcomb Dan T. | Enzymatic nucleic acid treatment of diseases or conditions related to levels of NF-kappa B |
| US6455689B1 (en) * | 1993-04-30 | 2002-09-24 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | Antisense-oligonucleotides for transforming growth factor-β (TGF-β) |
| GB9516268D0 (en) * | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
| JP2001521365A (ja) * | 1996-02-16 | 2001-11-06 | ミレニウム ファーマシューティカルズ，インコーポレーテッド | 心臓血管病の治療および診断のための組成物並びに方法 |
| US5783566A (en) * | 1996-05-10 | 1998-07-21 | California Institute Of Technology | Method for increasing or decreasing transfection efficiency |
| US5856462A (en) * | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
| PT963376E (pt) | 1996-12-11 | 2005-06-30 | Bristol Myers Squibb Co | Sistema procariotico duplamente hibrido |
| JPH10295381A (ja) * | 1997-04-23 | 1998-11-10 | Seibutsu Bunshi Kogaku Kenkyusho:Kk | 新規シグナル伝達因子、およびそれをコードする遺伝子 |
| WO1998053068A1 (en) * | 1997-05-20 | 1998-11-26 | Ludwig Institute For Cancer Research | Smad7 and uses thereof |
| JP2002510319A (ja) * | 1997-07-01 | 2002-04-02 | アイシス・ファーマシューティカルス・インコーポレーテッド | オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法 |
| JPH11335269A (ja) * | 1998-05-19 | 1999-12-07 | Hisamitsu Pharmaceut Co Inc | 遺伝子関連医薬の経口投与固形製剤 |
| EP1095154A2 (de) | 1998-07-10 | 2001-05-02 | Curagen Corporation | Interaktion von menschlichem beta-amyloid-protein (beta-app) mit menschlichem lon-protease (hslon) |
| US6479465B2 (en) * | 1999-03-24 | 2002-11-12 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of treating colitis using STAT-4 anti-sense oligonucleotides |
| US6159697A (en) * | 2000-01-19 | 2000-12-12 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad7 expression |
| US20020147140A1 (en) * | 2000-01-31 | 2002-10-10 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| CA2399550A1 (en) * | 2000-02-23 | 2001-08-30 | The Regents Of The University Of California | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
| US20020061569A1 (en) * | 2000-03-21 | 2002-05-23 | Robert Haselbeck | Identification of essential genes in prokaryotes |
| AUPR638101A0 (en) * | 2001-07-13 | 2001-08-09 | Bioa Pty Limited | Composition and method for treatment of disease |
| ES2388968T3 (es) * | 2001-11-02 | 2012-10-22 | Giuliani International Limited | Inhibidores de Smad7 para el tratamiento de enfermedades del SNC |
| JP2003135075A (ja) * | 2001-11-05 | 2003-05-13 | Research Association For Biotechnology | 新規な全長ｃＤＮＡ |
| EP1581634A4 (de) * | 2002-12-10 | 2006-10-25 | Scripps Research Inst | Verfahren zur behandlung von drogensucht und zum screening von pharmazeutika dafür |
| ITRM20030149A1 (it) * | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| US20040265833A1 (en) * | 2003-06-23 | 2004-12-30 | Cathy Lofton-Day | Methods and nucleic acids for the analysis of colorectal cell proliferative disorders |
| EP1722823A2 (de) * | 2004-02-27 | 2006-11-22 | Antisense Pharma GmbH | Pharmazeutische zusammensetzung |
| US20080015160A1 (en) * | 2005-11-04 | 2008-01-17 | Johji Inazawa | Method for detecting cancer and a method for suppressing cancer |
| WO2009151600A2 (en) * | 2008-06-10 | 2009-12-17 | Tufts University | Smad proteins control drosha-mediated mirna maturation |
| US8110355B2 (en) * | 2009-02-20 | 2012-02-07 | GenRemedy, LLC | Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis |
-
2002
- 2002-10-31 ES ES02790321T patent/ES2388968T3/es not_active Expired - Lifetime
- 2002-10-31 EP EP02790321A patent/EP1456380B1/de not_active Expired - Lifetime
- 2002-10-31 US US10/494,333 patent/US7700572B2/en not_active Expired - Fee Related
- 2002-10-31 AT AT02790321T patent/ATE554169T1/de active
- 2002-10-31 DK DK02790321.0T patent/DK1456380T3/da active
- 2002-10-31 SI SI200230992T patent/SI1456380T1/sl unknown
- 2002-10-31 AU AU2002363182A patent/AU2002363182A1/en not_active Abandoned
- 2002-10-31 PT PT02790321T patent/PT1456380E/pt unknown
- 2002-10-31 WO PCT/EP2002/012221 patent/WO2003037368A2/en not_active Ceased
-
2009
- 2009-09-23 US US12/565,629 patent/US20110207795A1/en not_active Abandoned
-
2012
- 2012-07-09 CY CY20121100612T patent/CY1112932T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US7700572B2 (en) | 2010-04-20 |
| US20050119203A1 (en) | 2005-06-02 |
| US20110207795A1 (en) | 2011-08-25 |
| WO2003037368A2 (en) | 2003-05-08 |
| EP1456380A2 (de) | 2004-09-15 |
| CY1112932T1 (el) | 2016-04-13 |
| EP1456380B1 (de) | 2012-04-18 |
| WO2003037368A3 (en) | 2004-03-11 |
| DK1456380T3 (da) | 2012-07-30 |
| PT1456380E (pt) | 2012-07-23 |
| AU2002363182A1 (en) | 2003-05-12 |
| SI1456380T1 (sl) | 2012-11-30 |
| ES2388968T3 (es) | 2012-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE554169T1 (de) | Smad7-inhibitoren zur behandlung von krankheiten des zns | |
| ATE337780T1 (de) | Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns | |
| ATE443043T1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
| PT971713E (pt) | Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao | |
| DE60118889D1 (de) | Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs | |
| DE50109156D1 (de) | Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd | |
| ATE390928T1 (de) | Zusammensetzungen zur behandlung von hauterkrankungen | |
| DE60140871D1 (de) | Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase | |
| ATE260653T1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
| ATE323490T1 (de) | Farnesyl-protein-transferasehemmer zur behandlung der entzündlichen darmerkrankung | |
| IL162384A0 (en) | Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases | |
| BRPI0411864A (pt) | combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas | |
| DK0989973T3 (da) | Chalconer med antiproliferativ aktivitet | |
| DE69918972D1 (de) | Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen | |
| MXPA05013226A (es) | Carbamatos de piperidina sustituidos, para el uso como inhibidores de la lipasa sensible a hormonas. | |
| DE60329326D1 (de) | Tace inhibitoren | |
| MXPA02011921A (es) | Inhibidores de dipeptidasa acida n-acetilada-alfa-enlazada para el tratamiento de trastornos retinianos y glaucona. | |
| DE60018704D1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
| ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
| HUP0103712A2 (hu) | Paroxetin sók, eljárás az előállításukra és gyógyászati alkalmazásuk | |
| ATE295724T1 (de) | Der duale inhibitor der cholesterylester und wachsester synthese avasimibe zur behandlung von erkrankungen des talgdrüse | |
| ATE536874T1 (de) | Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen | |
| DE60209886D1 (de) | Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen | |
| DE60220825D1 (de) | Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks | |
| ATE311901T1 (de) | Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten |